Erratum: BBA, a Derivative of 23-Hydroxybetulinic Acid, Potently Reverses ABCB1-Mediated Drug Resistance in Vitro and in Vivo (Molecular Pharmaceutics (2012) 9: 11 (3147−3159) DOI: 10.1021/mp300249s);BBA, a derivative of 23-hydroxybetulinic acid, potently reverses ABCB1-mediated drug resistance in vitro and in vivo

Molecular Pharmaceutics

Volumn 9, Issue 11, 2012, Pages 3147-3159

  Zhang, Dong Mei ^a   Shu, Chang ^a   Chen, Jun Jiang ^b   Sodani, Kamlesh ^b   Wang, Jiao ^a   Bhatnagar, Jaya ^c   Lan, Ping ^a   Ruan, Zhi Xiong ^a   Xiao, Zhi Jie ^b   Ambudkar, Suresh V ^c   Chen, Wei Min ^a   Chen, Zhe Sheng ^b   Ye, Wen Cai ^a  

^a JINAN UNIVERSITY   (China)

^b ST JOHN'S UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

ABCB1; ABCG2; BBA; multidrug resistance

Indexed keywords

23 O ( 1,4' BIPIPERIDINE 1 CARBONYL)BETULINIC ACID; ADENOSINE TRIPHOSPHATASE; ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; FIRTECAN; IDIOARYLAZIDOPRAZOSIN; IODOARYLAZIDOPRAZOSIN I 125; MESSENGER RNA; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PIPERAZINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; RHODAMINE 123; TERPENOID DERIVATIVE; UNCLASSIFIED DRUG; VERAPAMIL; VINBLASTINE; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG BINDING SITE; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENCY; ENZYME ACTIVITY; ENZYME SUBSTRATE; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MEDIATOR; MOLECULAR DOCKING; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PHOTOAFFINITY LABELING; PRIORITY JOURNAL; PROTEIN FUNCTION; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; TUMOR XENOGRAFT; WESTERN BLOTTING;

EID: 84868538356     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.3c00215     Document Type: Erratum

References (54)

1. Baguley, B. C. Multidrug resistance in cancer Methods Mol. Biol. 2010, 596, 1-14
2. Sodani, K.; Patel, A.; Kathawala, R. J.; Chen, Z. S. Multidrug resistance associated proteins in multidrug resistance Chin. J. Cancer 2012, 31, 58-72
3. Dean, M.; Hamon, Y.; Chimini, G. The human ATP-binding cassette (ABC) transporter superfamily J. Lipid Res. 2001, 42, 1007-1017
4. Cole, S.; Bhardwaj, G.; Gerlach, J.; Mackie, J.; Grant, C.; Almquist, K.; Stewart, A.; Kurz, E.; Duncan, A.; Deeley, R. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line Science 1992, 258, 1650-1654
5. Juliano, R. L.; Ling, V. A. surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants Biochim. Biophys. Acta 1976, 455, 152-162
6. Uchida, S.; Shimada, Y.; Watanabe, G.; Li, Z. G.; Hong, T.; Miyake, M.; Imamura, M. Motility-related protein (MRP-1/CD9) and KAI1/CD82 expression inversely correlate with lymph node metastasis in oesophageal squamous cell carcinoma Br. J. Cancer 1999, 79, 1168-1173
7. Doyle, L. A.; Yang, W.; Abruzzo, L. V.; Krogmann, T.; Gao, Y.; Rishi, A. K.; Ross, D. A multidrug resistance transporter from human MCF-7 breast cancer cells Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 15665-15670
8. Sarkadi, B.; Homolya, L.; Szakács, G.; Váradi, A. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system Physiol. Rev. 2006, 86, 1179-1236
9. Coley, H. M. Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors Methods Mol. Biol. 2010, 596, 341-358
10. Sikic, B. Pharmacologic approaches to reversing multidrug resistance Semin. Hematol. 1997, 34, 40-47
11. Tsuruo, T.; Iida, H.; Tsukagoshi, S.; Sakurai, Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil Cancer Res. 1981, 41, 1967-1972
12. Twentyman, P.; Fox, N.; White, D. Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multi-drug resistant human lung cancer cell line Br. J. Cancer 1987, 56, 55-57
13. Krishna, R.; Mayer, L. D. Multidrug resistance (MDR) in cancer: Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J Pharm. Sci. 2000, 11, 265-283
14. Tan, B.; Piwnica-Worms, D.; Ratner, L. Multidrug resistance transporters and modulation Curr. Opin. Oncol. 2000, 12, 450-458
15. Baer, M. R.; George, S. L.; Dodge, R. K.; OLoughlin, K. L.; Minderman, H.; Caligiuri, M. A.; Anastasi, J.; Powell, B. L.; Kolitz, J. E.; Schiffer, C. A. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720 Blood 2002, 100, 1224-1232
16. Nobili, S.; Landini, I.; Giglioni, B.; Mini, E. Pharmacological strategies for overcoming multidrug resistance Curr. Drug Targets 2006, 7, 861-879
17. Lee, C. H. Reversing agents for ATP-binding cassette (ABC) transporters: application in modulating multidrug resistance (MDR) Curr. Med. Chem.: Anti-Cancer Agents 2004, 4, 43-52
18. Shukla, S.; Wu, C. P.; Ambudkar, S. V. Development of inhibitors of ATP-binding cassette drug transporters-present status and challenges Expert Opin. Drug Metab. Toxicol. 2008, 4, 205-223
19. Mistry, P.; Stewart, A. J.; Dangerfield, W.; Okiji, S.; Liddle, C.; Bootle, D.; Plumb, J. A.; Templeton, D.; Charlton, P. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576 Cancer Res. 2001, 61, 749-758
20. Qi, F.; Li, A.; Inagaki, Y.; Gao, J.; Li, J.; Kokudo, N.; Li, X. K.; Tang, W. Chinese herbal medicines as adjuvant treatment during chemo- or radio-therapy for cancer Biosci. Trends 2010, 4, 297-307
21. Zhang, Y.; Liu, X.; Zuo, T.; Liu, Y.; Zhang, J. H. Tetramethylpyrazine reverses multidrug resistance in breast cancer cells through regulating the expression and function of P-glycoprotein Med. Oncol. 2011, 1-5
22. Wang, X. B.; Wang, S. S.; Zhang, Q. F.; Ming, L.; Li, H. L.; Ying, L.; Wang, J. N.; Zheng, F.; Guo, L. Y.; Xiang, J. Z. Inhibition of tetramethylpyrazine on P-gp, MRP2, MRP3 and MRP5 in multidrug resistant human hepatocellular carcinoma cells Oncol. Rep. 2010, 23, 211-215
23. Zhu, X. L.; Xu, W. L.; Lu, X. J.; Luo, W. J.; Zhou, L. L.; Chen, Q. Y. Mechanisms of preventive effect of tetrandrine on acquired multidrug resistance in K562 cells J. Exp. Hematol. 2011, 19, 363-366
24. Wei, N.; Sun, H.; Wang, F.; Liu, G. H1, a novel derivative of tetrandrine reverse P-glycoprotein-mediated multidrug resistance by inhibiting transport function and expression of P-glycoprotein Cancer Chemother. Pharmacol. 2011, 67, 1017-1025
25. Huang, M.; Jin, J.; Sun, H.; Liu, G. T. Reversal of P-glycoprotein- mediated multidrug resistance of cancer cells by five schizandrins isolated from the Chinese herb Fructus Schizandrae Cancer Chemother. Pharmacol. 2008, 62, 1015-1026
26. Zeng, R.; Zhou, Z. W.; Wu, C. F.; Zhou, Y. L. Reversal effect of aloe emodin liposomes on cisplatin resistance line A549/DDP human lung adenocarcinoma cells China J. Chin. Mater. Med. 2008, 33, 1443-1445
27. Zhang, H.; Yang, L.; Liu, S.; Ren, L. Study on active constituents of traditional Chinese medicine reversing multidrug resistance of tumor cells in vitro J. Chin. Med. Mater. 2001, 24, 655-657
28. Ji, Z. N.; Ye, W. C.; Liu, G. G.; Hsiao, W. 23-Hydroxybetulinic acid-mediated apoptosis is accompanied by decreases in bcl-2 expression and telomerase activity in HL-60 Cells Life Sci. 2002, 72, 1-9
29. Zhou, J. P.; Li, D.; Wu, X. M.; Ye, W. C.; Zhang, L. Y. Synthesis and antitumor activity of derivatives of 23-hydroxybetulinic acid Chin. Chem. Lett. 2007, 18, 1195-1198
30. Zheng, Y.; Zhou, F.; Wu, X.; Wen, X.; Li, Y.; Yan, B.; Zhang, J.; Hao, G.; Ye, W.; Wang, G. 23-Hydroxybetulinic acid from Pulsatilla chinensis (Bunge) Regel synergizes the antitumor activities of doxorubicin in vitro and in vivo J. Ethnopharmacol. 2010, 128, 615-622
31. Lan, P.; Wang, J.; Zhang, D. M.; Shu, C.; Cao, H. H.; Sun, P. H.; Wu, X. M.; Ye, W. C.; Chen, W. M. Synthesis and antiproliferative evaluation of 23-hydroxybetulinic acid derivatives Eur. J. Med. Chem. 2011, 217, 2490-2502
32. Cheung, J. Y.; Ong, R. C.; Suen, Y. K.; Ooi, V.; Wong, H. N.; Mak, T. C.; Fung, K. P.; Yu, B.; Kong, S. K. Polyphyllin D is a potent apoptosis inducer in drug-resistant HepG2 cells Cancer Lett. 2005, 217, 203-211
33. Fu, L.; Liang, Y.; Deng, L.; Ding, Y.; Chen, L.; Ye, Y.; Yang, X.; Pan, Q. Characterization of tetrandrine, a potent inhibitor of P-glycoprotein- mediated multidrug resistance Cancer Chemother. Pharmacol. 2004, 53, 349-356
34. Akiyama, S. I.; Fojo, A.; Hanover, J. A.; Pastan, I.; Gottesman, M. M. Isolation and genetic characterization of human KB cell lines resistant to multiple drugs Somatic Cell Mol. Genet. 1985, 11, 117-126
35. Taguchi, Y.; Yoshida, A.; Takada, Y.; Komano, T.; Ueda, K. Anti-cancer drugs and glutathione stimulate vanadate-induced trapping of nucleotide in multidrug resistance-associated protein (MRP) FEBS Lett. 1997, 401, 11-14
36. Robey, R.; Honjo, Y.; Morisaki, K.; Nadjem, T.; Runge, S.; Risbood, M.; Poruchynsky, M.; Bates, S. Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity Br. J. Cancer 2003, 89, 1971-1978
37. Dai, C.; Tiwari, A. K.; Wu, C. P.; Su, X.; Wang, S. R.; Liu, D.; Ashby, C. R.; Huang, Y.; Robey, R. W.; Liang, Y. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2 Cancer Res. 2008, 68, 7905-7914
38. Ambudkar, S. V. Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells Methods Enzymol. 1998, 292, 504-514
39. Kerr, K. M.; Sauna, Z. E.; Ambudkar, S. V. Correlation between steady-state ATP hydrolysis and vanadate-induced ADP trapping in human P-glycoprotein J. Biol. Chem. 2001, 276, 8657-8664
40. Aller, S. G.; Yu, J.; Ward, A.; Weng, Y.; Chittaboina, S.; Zhuo, R.; Harrell, P. M.; Trinh, Y. T.; Zhang, Q.; Urbatsch, I. L.; Chang, G. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding Science 2009, 323, 1718-1722
41. Fu, L.; Zhang, Y.; Liang, Y.; Yang, X.; Pan, Q. The multidrug resistance of tumour cells was reversed by tetrandrine in vitro and in xenografts derived from human breast adenocarcinoma MCF-7/adr cells Eur. J. Cancer 2002, 38, 418-426
42. Mi, Y.; Liang, Y.; Huang, H.; Zhao, H.; Wu, C. P.; Wang, F.; Tao, L.; Zhang, C.; Dai, C. L.; Tiwari, A. K. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters Cancer Res. 2010, 70, 7981-7991
43. Honjo, Y.; Hrycyna, C. A.; Yan, Q. W.; Medina-Perez, W. Y.; Robey, R. W.; van de Laar, A.; Litman, T.; Dean, M.; Bates, S. E. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells Cancer Res. 2001, 61, 6635-6639
44. Newman, M. J.; Rodarte, J. C.; Benbatoul, K. D.; Romano, S. J.; Zhang, C.; Krane, S.; Moran, E. J.; Uyeda, R. T.; Dixon, R.; Guns, E. S.; Mayer, L. D. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance Cancer Res. 2000, 60, 2964-2972
45. Reed, J. C.; Miyashita, T.; Takayama, S.; Wang, H. G.; Sato, T.; Krajewski, S.; Aimé-Sempé, C.; Bodrug, S.; Kitada, S.; Hanada, M. BCL-2 family proteins: Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy J. Cell. Biochem. 1996, 60, 23-32
46. Wang, Y.; Wang, G. C.; Zhao, H. N.; Fan, C. L.; Ye, W. C. RP-HPLC determination of 23-hydroxybetulinic acid in the roots of Pulsatilla chinensis Chin. J. Pharm. Anal. 2007, 27, 13-15
47. Zhao, H. N.; Wang, Y.; Su, W. K.; Zhang, X. Q.; Ye, W. C. Preparation of 23-hydroxybetulinic Acid from the Roots of Pulsatilla chinensis J. Chin. Med. Mater. 2007, 30, 170-172
48. Munoz-Martinez, F.; Lu, P.; Cortes-Selva, F.; Perez-Victoria, J. M.; Jimenez, I. A.; Ravelo, A. G.; Sharom, F. J.; Gamarro, F.; Castanys, S. Celastraceae sesquiterpenes as a new class of modulators that bind specifically to human P-glycoprotein and reverse cellular multidrug resistance Cancer Res. 2004, 64, 7130-7138
49. Thomas, H.; Coley, H. M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein Cancer Control 2003, 10, 159-165
50. West, K. A.; Sianna Castillo, S.; Dennis, P. A. Activation of the PI3K/Akt pathway and chemotherapeutic resistance Drug Resist. Updates 2002, 5, 234-248
51. Katayama, K.; Yoshioka, S.; Tsukahara, S.; Mitsuhashi, J.; Sugimoto, Y. Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein Mol. Cancer Ther. 2007, 6, 2092-2102
52. Kim, D.; Dan, H. C.; Park, S.; Yang, L.; Liu, Q.; Kaneko, S.; Ning, J.; He, L.; Yang, H.; Sun, M. Akt/PKB signaling mechanisms in cancer and chemoresistance Front. Biosci. 2005, 10, 975-987
53. Wang, J.; Chan, J. Y.; Fong, C. C.; Tzang, C. H.; Fung, K. P.; Yang, M. Transcriptional analysis of doxorubicin-induced cytotoxicity and resistance in human hepatocellular carcinoma cell lines Liver Int. 2009, 29, 1338-1347
54. Jiang, L.; Chan, J. Y.; Fung, K. P. Epigenetic loss of CDH1 correlates with multidrug resistance in human hepatocellular carcinoma cells Biochem. Biophys. Res. Commun. 2012, 422, 739-744